Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Abstract Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAFV600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + MEKi caused durable melanoma regression in an immune-mediated manner. BRAFi + MEKi treatment promoted cleavage of gasdermin E (GSDME) and release of HMGB1, markers of pyroptotic cell death. GSDME-deficient melanoma showed defective HMGB1 release, reduced tumor-associated T cell and activated dendritic cell infiltrates in response to BRAFi + MEKi, and more frequent tumor regrowth after drug removal. Importantly, BRAFi + MEKi–resistant disease lacked pyroptosis markers and showed decreased intratumoral T-cell infiltration but was sensitive to pyroptosis-inducing chemotherapy. These data implicate BRAFi + MEKi–induced pyroptosis in antitumor immune responses and highlight new therapeutic strategies for resistant melanoma. Significance: Targeted inhibitors and immune checkpoint agents have advanced the care of patients with melanoma; however, detailed knowledge of the intersection between these two research areas is lacking. We describe a molecular mechanism of targeted inhibitor regulation of an immune-stimulatory form of cell death and provide a proof-of-principle salvage therapy concept for inhibitor-resistant melanoma. See related commentary by Smalley, p. 176. This article is highlighted in the In This Issue feature, p. 161
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“induction of ICD (Box 1) (Erkes et al., 2020; Wang et al., 2020a)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Erkes et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedGSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 3×
“We confirmed the ability of etoposide and also tested doxorubicin, a known chemotherapeutic inducer of pyroptosis, for ability to cause GSDME cleavage in CRT cell lines (31,32,34).”
BackgroundSelf-citationToll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundRelease of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundClassification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Self-citationInflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202 · cited 1×
“It has recently been shown that the intrinsic apoptotic pathway intersects with a distinct form of cell death termed pyroptosis that is gasderminmediated and involves pore-based release of immune stimulatory factors (28-31).”
BackgroundChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 1×
“This pore formation causes the release of immune stimulants, including HMGB1, which are able to induce dendritic cell (DC) activation and, in turn, propagate antitumor T-cell activity (32, 33, 35).”
BackgroundImmunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · cited 1×
“This pore formation causes the release of immune stimulants, including HMGB1, which are able to induce dendritic cell (DC) activation and, in turn, propagate antitumor T-cell activity (32, 33, 35).”
BackgroundPyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death
Shi, J., Gao, W., & Shao, F. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.10.004 · Cited by 3,088 · cited 1×
“It has recently been shown that the intrinsic apoptotic pathway intersects with a distinct form of cell death termed pyroptosis that is gasderminmediated and involves pore-based release of immune stimulatory factors (28-31).”
BackgroundRogers, C., Fernandes-Alnemri, T., Mayes, L., Alnemri, D., Cingolani, G., & Alnemri, E. S. (2017) · Nature Communications · doi:10.1038/ncomms14128 · Cited by 1,510 · cited 4×
“We have recently shown that pyroptosis can be initiated by caspase-3–mediated GSDME cleavage in response to various apoptotic stimuli (32, 34).”
BackgroundInfluentialSelf-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490 · cited 1×
“Agents targeting the MEK-ERK1/2 pathway or immune checkpoints have emerged as effective treatment modalities that significantly improve progression-free survival and overall survival for stage III and stage IV melanoma patients (2-4).”
BackgroundSchadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31559-9 · Cited by 1,488
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 1×
“Although several melanoma cell-autonomous mechanisms of resistance to BRAFi and/or MEKi have been established (5, 6, 48), it has remained unclear how antimelanoma immune responses in the tumor microenvironment can be leveraged to overcome treatment resistance.”
BackgroundA Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429 · cited 1×
“The immune cell gene set analysis was performed as published previously (56).”
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346 · cited 5×
“When the volume reached approximately 50 to 250 mm3 animals were fed with either vehicle control chow or combination BRAFi + MEKi chow (200 ppm PLX4720 plus 7 ppm PD0325901).”
BackgroundInfluentialFrederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944 · cited 2×
“Generally, BRAFi and/or MEKi efficacy correlates with T cell infiltration of tumors, while the loss of intra-tumoral CD8+ T cells and influx of tumor-associated macrophages are associated with acquired resistance in metastatic melanoma (10,17,19,24).”
BackgroundRogers, C., Erkes, D. A., Nardone, A., Aplin, A. E., Fernandes-Alnemri, T., & Alnemri, E. S. (2019) · Nature Communications · doi:10.1038/s41467-019-09397-2 · Cited by 826 · cited 3×
“We have recently shown that pyroptosis can be initiated by caspase-3–mediated GSDME cleavage in response to various apoptotic stimuli (32, 34).”
BackgroundSelf-citationEbert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713 · cited 1×
“In addition, in preclinical models, CSF1R inhibitors targeting macrophage accumulation improved efficacy of BRAFi (18), and the efficacy of MEKi can be improved by targeting the PD-1/PD-L1/L2 axis (19, 22).”
BackgroundSelective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652 · cited 1×
“BRAFi increase MHC expression and induce CD4+ and CD8+ T cell-dependent anti-tumor immunity (9-19).”
BackgroundNon-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 600 · cited 4×
“RESULTS Therapeutic Efficacy of BRAFi + MEKi Combination Treatment In Vivo Depends on an Intact Immune System Acquired resistance to BRAFi + MEKi treatment is accompanied by reduced intratumoral infiltration of T cells (17).”
BackgroundResultInfluentialImproved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comin-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 563 · cited 1×
“Next, we analyzed the release and cell-surface expression of immune stimulants from dying cells that could potentiate antitumor immune responses in part via effects on DCs, specifically HMGB1 and calreticulin (24, 25).”
MethodProgrammed necrosis in inflammation: Toward identification of the effector molecules
Wallach, D., Kang, T.-B., Dillon, C. P., & Green, D. R. (2016) · Science · doi:10.1126/science.aaf2154 · Cited by 544 · cited 1×
“It has recently been shown that the intrinsic apoptotic pathway intersects with a distinct form of cell death termed pyroptosis that is gasderminmediated and involves pore-based release of immune stimulatory factors (28-31).”
BackgroundMojo Hand, a TALEN design tool for genome editing applications
Neff, K. L., Argue, D. P., Ma, A. C., Lee, H. B., Clark, K. J., & Ekker, S. C. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-1 · Cited by 529
Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.277 · Cited by 493 · cited 1×
“To this end, we cultured splenocytes from Pmel-1 mice (a transgenic mouse model with T cells specific for the melanoma antigen gp100) with conditioned medium from BRAFi + MEKi–treated tumor cells (42).”
MethodCleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells
Yu, J., Li, S., Qi, J., Chen, Z., Wu, Y., Guo, J., Wang, K., Sun, X., & Zheng, J. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1441-4 · Cited by 483 · cited 1×
“The release of additional inflammatory factors has been associated with of pyroptotic cell death (40, 41), and we did detect BRAFi + MEKi–dependent release of another inflammatory mediator, IL1α, from melanoma cells (Fig.”
BackgroundWagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · cited 1×
“Acquired resistance is often due to re-activation of the MEK-ERK1/2 pathway caused by mechanisms including NRAS mutation, increased BRAF copy number and aberrant BRAF splicing (5-7).”
BackgroundMoriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 345 · cited 1×
“Although several melanoma cell-autonomous mechanisms of resistance to BRAFi and/or MEKi have been established (5, 6, 48), it has remained unclear how antimelanoma immune responses in the tumor microenvironment can be leveraged to overcome treatment resistance.”
BackgroundDabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0448-9 · Cited by 324 · cited 1×
“These findings are increasingly important as BRAFi + MEKi therapy in combination with immune checkpoint inhibition is being tested in patients with advanced melanoma with promising efficacy albeit toxicity challenges (49-51).”
BackgroundCombined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Ribas, A., Lawrence, D., Atkinson, V., Agarwal, S., Miller, W. H., Carlino, M. S., Fisher, R., Long, G. V., Hodi, F. S., Tsoi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0476-5 · Cited by 323 · cited 1×
“These findings are increasingly important as BRAFi + MEKi therapy in combination with immune checkpoint inhibition is being tested in patients with advanced melanoma with promising efficacy albeit toxicity challenges (49-51).”
BackgroundThe YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Meeth, K., Wang, J. X., Micevic, G., Damsky, W., & Bosenberg, M. W. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12498 · Cited by 318
Amaria, R. N., Prieto, P. A., Tetzlaff, M. T., Reuben, A., Andrews, M. C., Ross, M. I., Glitza, I. C., Cormier, J., Hwu, W.-J., Tawbi, H. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30015-9 · Cited by 299 · cited 1×
“Agents targeting the MEK-ERK1/2 pathway or immune checkpoints have emerged as effective treatment modalities that significantly improve progression-free survival and overall survival for stage III and stage IV melanoma patients (2-4).”
BackgroundLu, H., Zhang, S., Wu, J., Chen, M., Cai, M.-C., Fu, Y., Li, W., Wang, J., Zhao, X., Yu, Z., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1478 · Cited by 271 · cited 2×
“Our findings are supported by a recent study that found that MEKi promote GSDME cleavage in lung cancer (36), although again antitumor immune responses were not assessed in that report.”
BackgroundResultResponse to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Cooper, Z. A., Juneja, V. R., Sage, P. T., Frederick, D. T., Piris, A., Mitra, D., Lo, J. A., Hodi, F. S., Freeman, G. J., Bosenberg, M. W., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0215 · Cited by 257 · cited 1×
“BRAFi increase MHC expression and induce CD4+ and CD8+ T cell-dependent anti-tumor immunity (9-19).”
BackgroundTian, Y., Xie, Q., He, J., Luo, X., Zhou, T., Liu, Y., Huang, Z., Tian, Y., Sun, D., & Yao, K. (2015) · BMC Cancer · doi:10.1186/1471-2407-15-1 · Cited by 239
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Sullivan, R. J., Hamid, O., Gonzalez, R., Infante, J. R., Patel, M. R., Hodi, F. S., Lewis, K. D., Tawbi, H. A., Hernandez, G., Wongchenko, M. J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0474-7 · Cited by 238
BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
Koya, R. C., Mok, S., Otte, N., Blacketor, K. J., Comin-Anduix, B., Tumeh, P. C., Minasyan, A., Graham, N. A., Graeber, T. G., Chodon, T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2837 · Cited by 234 · cited 1×
“BRAFi increase MHC expression and induce CD4+ and CD8+ T cell-dependent anti-tumor immunity (9-19).”
BackgroundEigenbrod, T., Park, J.-H., Harder, J., Iwakura, Y., & Núñez, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8194 · Cited by 228 · cited 1×
“The release of additional inflammatory factors has been associated with of pyroptotic cell death (40, 41), and we did detect BRAFi + MEKi–dependent release of another inflammatory mediator, IL1α, from melanoma cells (Fig.”
BackgroundSong, C., Piva, M., Sun, L., Hong, A., Moriceau, G., Kong, X., Zhang, H., Lomeli, S., Qian, J., Yu, C. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0401 · Cited by 158 · cited 1×
“In addition, in preclinical models, CSF1R inhibitors targeting macrophage accumulation improved efficacy of BRAFi (18), and the efficacy of MEKi can be improved by targeting the PD-1/PD-L1/L2 axis (19, 22).”
BackgroundBeck, D., Niessner, H., Smalley, K. S. M., Flaherty, K., Paraiso, K. H. T., Busch, C., Sinnberg, T., Vasseur, S., Iovanna, J. L., Drießen, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003057 · Cited by 146 · cited 1×
“Mechanistically, inhibition of MEK-ERK1/2 signaling induces BIM-EL and BMF-mediated mitochondrial depolarization, leading to cytochrome C release and activation of caspase-3 (16,25-27).”
BackgroundCo-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Kwong, L. N., Boland, G. M., Frederick, D. T., Helms, T. L., Akid, A. T., Miller, J. P., Jiang, S., Cooper, Z. A., Song, X., Seth, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78954 · Cited by 128 · cited 4×
“RNA-seq Data Analysis RNA-seq data were collected from European Genome–phenome Archive, EGAS000010000992 (39) and from the GSE99898 dataset (43).”
MethodInfluentialImmune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ
Ho, P.-C., Meeth, K. M., Tsui, Y.-C., Srivastava, B., Bosenberg, M. W., & Kaech, S. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3461 · Cited by 126 · cited 1×
“BRAFi increase MHC expression and induce CD4+ and CD8+ T cell-dependent anti-tumor immunity (9-19).”
BackgroundDushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A., Luen, S. J., Mansour, M., Kershaw, M. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00728-9 · Cited by 124 · cited 1×
“S3D and S3E), consistent with previous publications suggesting that MEKi inhibits T-cell function (21, 23).”
ResultDFNA5 (ICERE‐1) contributes to acquired etoposide resistance in melanoma cells
Lage, H., Helmbach, H., Grottke, C., Dietel, M., & Schadendorf, D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02304-3 · Cited by 115
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Kakavand, H., Rawson, R. V., Pupo, G. M., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Kefford, R. F., Howle, J. R., Saw, R. P. M., Thompson, J. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1688 · Cited by 91 · cited 1×
“RNA-seq Data Analysis RNA-seq data were collected from European Genome–phenome Archive, EGAS000010000992 (39) and from the GSE99898 dataset (43).”
MethodMultiple murine BRafV600E melanoma cell lines with sensitivity to PLX4032
Jenkins, M. H., Steinberg, S. M., Alexander, M. P., Fisher, J. L., Ernstoff, M. S., Turk, M. J., Mullins, D. W., & Brinckerhoff, C. E. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12220 · Cited by 89
Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma
Ilieva, K. M., Correa, I., Josephs, D. H., Karagiannis, P., Egbuniwe, I. U., Cafferkey, M. J., Spicer, J. F., Harries, M., Nestle, F. O., Lacy, K. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0290 · Cited by 87 · cited 1×
“BRAFi increase MHC expression and induce CD4+ and CD8+ T cell-dependent anti-tumor immunity (9-19).”
BackgroundHenderson, Y. C., Chen, Y., Frederick, M. J., Lai, S. Y., & Clayman, G. L. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0062 · Cited by 80 · cited 5×
“When the volume reached approximately 50 to 250 mm3 animals were fed with either vehicle control chow or combination BRAFi + MEKi chow (200 ppm PLX4720 plus 7 ppm PD0325901).”
BackgroundInfluentialResistance to RAF Inhibitors Revisited
Hartsough, E., Shao, Y., & Aplin, A. E. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.358 · Cited by 75 · cited 2×
“Although several melanoma cell-autonomous mechanisms of resistance to BRAFi and/or MEKi have been established (5, 6, 48), it has remained unclear how antimelanoma immune responses in the tumor microenvironment can be leveraged to overcome treatment resistance.”
BackgroundResultSelf-citationSilva, I. P., & Long, G. V. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000405 · Cited by 74 · cited 1×
“Agents targeting the MEK-ERK1/2 pathway or immune checkpoints have emerged as effective treatment modalities that significantly improve progression-free survival and overall survival for stage III and stage IV melanoma patients (2-4).”
BackgroundAllegrezza, M. J., Rutkowski, M. R., Stephen, T. L., Svoronos, N., Perales-Puchalt, A., Nguyen, J. M., Payne, K. K., Singhal, S., Eruslanov, E. B., Tchou, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1308 · Cited by 63 · cited 1×
“S3D and S3E), consistent with previous publications suggesting that MEKi inhibits T-cell function (21, 23).”
ResultPrete, A. C. L., Maria, D. A., Rodrigues, D. G., Valduga, C. J., Ibañez, O. M., & Maranhão, R. C. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.6.0010 · Cited by 59 · cited 1×
“For etoposide experiments, mice were treated with intraperitoneal injections of 17 M/animal of etoposide following the schedule outlined in Supplemental Figure 7E and F (55).”
MethodFibroblasts Protect Melanoma Cells from the Cytotoxic Effects of Doxorubicin
Tiago, M., de Oliveira, E. M., Brohem, C. A., Pennacchi, P. C., Paes, R. D., Haga, R. B., Campa, A., de Moraes Barros, S. B., Smalley, K. S., & Maria-Engler, S. S. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2013.0473 · Cited by 55 · cited 1×
“5 μM) and doxorubicin (1 μM) concentrations were based upon previous publications (59-61).”
BackgroundInhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition
Mok, S., Tsoi, J., Koya, R. C., Hu-Lieskovan, S., West, B. L., Bollag, G., Graeber, T. G., & Ribas, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1377-8 · Cited by 54 · cited 1×
“In addition, in preclinical models, CSF1R inhibitors targeting macrophage accumulation improved efficacy of BRAFi (18), and the efficacy of MEKi can be improved by targeting the PD-1/PD-L1/L2 axis (19, 22).”
BackgroundNiessner, H., Sinnberg, T. W., Kosnopfel, C., Smalley, K. S. M., Beck, D., Praetorius, C., Mai, M., Beissert, S., Kulms, D., Schaller, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0098 · Cited by 52 · cited 1×
“Since BRAFi + MEKi treatment induces caspase-3 activation (44), we tested for GSDME processing in melanoma cell lines.”
MethodThe association of alcohol consumption with mammographic density in a multiethnic urban population
Quandt, Z., Flom, J. D., Tehranifar, P., Reynolds, D., Terry, M. B., & McDonald, J. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1094-3 · Cited by 51
Lai, F., Guo, S. T., Jin, L., Jiang, C. C., Wang, C. Y., Croft, A., Chi, M. N., Tseng, H.-Y., Farrelly, M., Atmadibrata, B., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.192 · Cited by 48 · cited 1×
“Although previous work demonstrated that the combination of BRAFi plus HDAC inhibitors induced release of HMGB1 from melanoma (47), our data underscore the mechanistic role of GSDME in HMGB1 release and effects on antimelanoma immunity.”
ResultRAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells
Berger, A., Quast, S.-A., Plötz, M., Kuhn, N. F., Trefzer, U., & Eberle, J. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.347 · Cited by 38 · cited 1×
“Next, we analyzed the release and cell-surface expression of immune stimulants from dying cells that could potentiate antitumor immune responses in part via effects on DCs, specifically HMGB1 and calreticulin (24, 25).”
MethodSelf-citationDoes It MEK a Difference? Understanding Immune Effects of Targeted Therapy
Cooper, Z. A., Reuben, A., Austin-Breneman, J. L., & Wargo, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0363 · Cited by 34 · cited 2×
“BRAFi increase MHC expression and induce CD4+ and CD8+ T cell-dependent anti-tumor immunity (9-19).”
BackgroundIL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors
Allegrezza, M. J., Rutkowski, M. R., Stephen, T. L., Svoronos, N., Tesone, A. J., Perales-Puchalt, A., Nguyen, J. M., Sarmin, F., Sheen, M. R., Jeng, E. K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2808 · Cited by 33 · cited 2×
“Furthermore, MEKi improve anti-cancer T cell responses by impairing T-cell receptor (TCR)mediated apoptosis of tumor antigen-specific T cells (19-23).”
BackgroundWiggins, K. R., Davis, V., Phadke, D. P., Shah, R., & Archer, T. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-3928 · Cited by 27
Sanchez, I. M., Purwin, T. J., Chervoneva, I., Erkes, D. A., Nguyen, M. Q., Davies, M. A., Nathanson, K. L., Kemper, K., Peeper, D. S., & Aplin, A. E. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1056 · Cited by 26 · cited 1×
“A375-derived CRT cells were published previously (54).”
Self-citationEtoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits
Calvani, M., Bianchini, F., Taddei, M. L., Becatti, M., Giannoni, E., Chiarugi, P., & Calorini, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9939 · Cited by 22 · cited 1×
“5 μM) and doxorubicin (1 μM) concentrations were based upon previous publications (59-61).”
BackgroundSavojardo, C., Fariselli, P., Martelli, P. L., & Casadio, R. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-s1-s10 · Cited by 17
On the TRAIL to Overcome BRAF-Inhibitor Resistance
Geserick, P., Herlyn, M., & Leverkus, M. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.348 · Cited by 9 · cited 1×
“Mechanistically, inhibition of MEK-ERK1/2 signaling induces BIM-EL and BMF-mediated mitochondrial depolarization, leading to cytochrome C release and activation of caspase-3 (16,25-27).”
Background
Cited by
Pyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Hou, J., Zhao, R., Xia, W., Chang, C.-W., You, Y., Hsu, J.-M., Nie, L., Chen, Y., Wang, Y.-C., Liu, C., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0575-z · Cited by 962
Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
“For instance, combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) modulate the TME by triggering pyroptosis [182].”
BackgroundRegulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
“A study in BRAFi+MEKi-resistant melanoma by using etoposide to reinduce pyroptosis, inhibition of the ERK1/2 pathway, and cleavage of GSDME-induced pyroptosis produced a more potent antitumor immune response, overcoming treatment resistance.(470) It is suggested that targeting this regulated cell death pathway represe…”
Background
Metadata
- Authors
- Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., & Aplin, A. E.
- Affiliations
- Thomas Jefferson University (US)
- Corresponding author
- Alnemri, Emad S.
- Aplin, Andrew E.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-02-01
- Volume
- 10
- Issue
- 2
- Pages
- 254-269
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7007378
- OpenAlex
- W2993434511
- Cited by
- 459
- References
- 67
- Citations by year
- 2026: 38 · 2025: 52 · 2024: 78 · 2023: 84 · 2022: 114 · 2021: 72 · 2020: 21
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (CA196278, CA160495, CA182635, CA207855)
- Dr. Ralph and Marian Falk Medical Research Trust (N/A)
- HHS | National Institutes of Health (AR055398, AR074564)
- U.S. Department of Defense (PC150650)
- American Cancer Society (PF-18-096-01-LIB)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- BRAF inhibitors, MEK inhibitors, pyroptosis, gasdermin E, HMGB1, tumor immune microenvironment, antitumor immunity, T cell infiltration, dendritic cells, drug resistance, salvage therapy, targeted therapy
- MeSH terms
- Pyroptosis, Proof of Concept Study, Immune Checkpoint Inhibitors, Animals, Antineoplastic Combined Chemotherapy Protocols, Dendritic Cells, Disease Models, Animal, Female, Humans, Male, Melanoma, Mutation, Skin Neoplasms, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.